David G. Gaiero - 20 Dec 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role
Chief Financial Officer
Signature
/s/ Adam M. Veness, as attorney-in-fact for David Gaiero
Issuer symbol
N/A
Transactions as of
20 Dec 2021
Net transactions value
+$6,888
Form type
4
Filing time
07 Feb 2023, 15:38:17 UTC
Previous filing
17 Jun 2021
Next filing
24 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT Common Stock Options Exercise $6,888 +4,100 $1.68 4,100 20 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Stock Option (Right to Buy) Options Exercise $0 -4,100 -5.3% $0.000000 73,639 20 Dec 2021 Common Stock 4,100 $1.68 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Due to rounding in connection with the Issuer's reverse stock split during its initial public offering, the exercise price for this option was immaterially incorrect as reported on the Reporting Person's Form 3 filing on June 17, 2021, and has been corrected in this Form 4.
F2 The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney